Biotechnology Assets Sa Stock Total Asset
| BST Stock | 0.34 0.01 3.03% |
Biotechnology Assets SA fundamentals help investors to digest information that contributes to Biotechnology Assets' financial success or failures. It also enables traders to predict the movement of Biotechnology Stock. The fundamental analysis module provides a way to measure Biotechnology Assets' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biotechnology Assets stock.
Biotechnology |
Biotechnology Assets SA Company Total Asset Analysis
Biotechnology Assets' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, Biotechnology Assets SA has a Total Asset of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The total asset for all Spain stocks is 100.0% higher than that of the company.
Biotechnology Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biotechnology Assets' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biotechnology Assets could also be used in its relative valuation, which is a method of valuing Biotechnology Assets by comparing valuation metrics of similar companies.Biotechnology Assets is currently under evaluation in total asset category among its peers.
Biotechnology Fundamentals
| Return On Equity | -0.74 | |||
| Return On Asset | -0.0647 | |||
| Profit Margin | (0.92) % | |||
| Operating Margin | (0.63) % | |||
| Shares Outstanding | 48.35 M | |||
| Shares Owned By Insiders | 51.21 % | |||
| Revenue | 3.28 M | |||
| Gross Profit | 3.01 M | |||
| EBITDA | (1.04 M) | |||
| Book Value Per Share | 0.1 X | |||
| Number Of Employees | 33 | |||
| Beta | 1.51 | |||
| Market Capitalization | 13.64 M | |||
| Annual Yield | 0.53 % |
About Biotechnology Assets Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biotechnology Assets SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotechnology Assets using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotechnology Assets SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Biotechnology Stock
Biotechnology Assets financial ratios help investors to determine whether Biotechnology Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotechnology with respect to the benefits of owning Biotechnology Assets security.